Q1 EPS Forecast for Solid Biosciences Reduced by Analyst

Solid Biosciences Inc. (NASDAQ:SLDB) – Research analysts at Leerink Partnrs dropped their Q1 2025 earnings per share (EPS) estimates for shares of Solid Biosciences in a report issued on Thursday, January 9th. Leerink Partnrs analyst J. Schwartz now expects that the company will earn ($0.81) per share for the quarter, down from their previous forecast of ($0.80). The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.85) per share. Leerink Partnrs also issued estimates for Solid Biosciences’ Q2 2025 earnings at ($0.82) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($3.17) EPS and FY2026 earnings at ($2.98) EPS.

Solid Biosciences (NASDAQ:SLDB) last released its earnings results on Wednesday, November 6th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.12).

A number of other brokerages have also weighed in on SLDB. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Solid Biosciences in a research report on Friday. Citizens Jmp upgraded Solid Biosciences to a “strong-buy” rating in a research report on Tuesday, December 10th. JMP Securities began coverage on shares of Solid Biosciences in a research report on Tuesday, December 10th. They issued an “outperform” rating and a $15.00 price target on the stock. Truist Financial began coverage on shares of Solid Biosciences in a research report on Wednesday, January 8th. They set a “buy” rating and a $16.00 price objective for the company. Finally, JPMorgan Chase & Co. decreased their target price on shares of Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. Nine analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $15.30.

Solid Biosciences Stock Performance

Shares of SLDB stock opened at $3.68 on Monday. The firm has a market capitalization of $147.03 million, a PE ratio of -1.21 and a beta of 2.05. The stock has a fifty day simple moving average of $4.88 and a two-hundred day simple moving average of $6.60. Solid Biosciences has a 52-week low of $3.42 and a 52-week high of $15.05.

Insider Buying and Selling at Solid Biosciences

In other Solid Biosciences news, COO David T. Howton sold 5,072 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total value of $28,403.20. Following the completion of the transaction, the chief operating officer now directly owns 15,663 shares in the company, valued at approximately $87,712.80. The trade was a 24.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jessie Hanrahan sold 4,610 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total transaction of $25,816.00. Following the completion of the sale, the insider now owns 14,235 shares in the company, valued at $79,716. This represents a 24.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,775 shares of company stock valued at $140,008 in the last ninety days. Corporate insiders own 13.63% of the company’s stock.

Hedge Funds Weigh In On Solid Biosciences

A number of large investors have recently made changes to their positions in SLDB. Barclays PLC boosted its stake in Solid Biosciences by 412.1% in the 3rd quarter. Barclays PLC now owns 62,856 shares of the company’s stock worth $439,000 after purchasing an additional 50,582 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Solid Biosciences during the third quarter worth $121,000. Wellington Management Group LLP grew its holdings in shares of Solid Biosciences by 183.6% during the third quarter. Wellington Management Group LLP now owns 119,804 shares of the company’s stock valued at $835,000 after buying an additional 77,564 shares during the last quarter. State Street Corp increased its position in shares of Solid Biosciences by 9.2% in the 3rd quarter. State Street Corp now owns 441,540 shares of the company’s stock valued at $3,078,000 after acquiring an additional 37,130 shares during the period. Finally, Point72 Asset Management L.P. raised its stake in Solid Biosciences by 292.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 443,010 shares of the company’s stock worth $3,088,000 after acquiring an additional 330,234 shares during the last quarter. 81.46% of the stock is owned by institutional investors and hedge funds.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.